All In Biotech

Drug Trial Radar · NCT06816524

The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency

The Effects of Iron Treatment on Malaria, Typhoid and Measles Vaccine Response in Kenyan Infants With Iron Deficiency: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

Mar 13, 2026

Primary completion

Dec 31, 2027

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Nicole StoffelAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jomo Kenyatta University of Agriculture and Technology; University of Oxford - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences; Radboud University Medical Center; National Institute for Public Health and the Environment (RIVM)
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination. In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M, Typhim VI and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.

Conditions

  • Iron Deficiencies

Interventions

  • Iron syrupDietary supplement

    Iron syrup administered daily from 6 to 10 months of age.

  • Multivitamin syrupDietary supplement

    Multivitamin syrup administered daily from 6 to 10 months of age.

  • R21-Matrix/M Vaccine (malaria vaccine)Biological

    R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age.

  • Measles-Rubella vaccineBiological

    Measles-Rubella vaccine administered at 9 months of age.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. NANP-specific IgGTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
  2. Anti-measles IgGTime frame: At 10 months of age (1 month after MR vaccine administration)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Msambweni District Hospital

    Msambweni, Kwale County, Kenya · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.